Sorrento Therapeutics
(NASDAQ: SRNE)

 Fact Sheet

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB™ library"), clinical stage immuno-cellular therapies ("CAR-T"), intracellular targeting antibodies ("iTAbs"), antibody-drug conjugates ("ADC"), and clinical stage oncolytic virus ("Sephrevir®").

Sorrento's commitment to life-enhancing therapies for cancer patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule in Resiniferatoxin ("RTX") and ZTlido. Resiniferatoxin is completing a phase IB trial in terminal cancer patients. ZTlido is in regulatory review following NDA re-submission.

Find a broker to begin trading SRNE now

Company Name Sorrento Therapeutics
Market/Symbol NASDAQ: SRNE
Recent Price
Market Cap $668.34M
Avg. Daily Vol. (3m) 3,267,125
Price/Book N/A
Price/Cash Flow N/A
As of May. 18, 2018
*Source: QuoteMedia


Begin trading SRNE

 Find Broker

SIGN UP FOR EMAIL ALERTS

BE THE FIRST TO RECEIVE BREAKING NEWS

Recent Company Videos


Sorrento Therapeutics: Exclusive Investor Presentation

Feb. 2, 2018

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets…


Sorrento Therapeutics Latest News


Latest Investor Presentation

Latest Investor Presentation

 View Full Presentation |  Download

Ask the CEO



Meet The Board of Directors

David H. Deming

banker with TAG Healthcare Advisors

Dorman Followwill

Senior Partner

Kim D. Janda

Director

Henry Ji

Chairman

David Lemus

Non-executive

Jaisim Shah

CEO

Yue Alexander Wu

Co-founder, President, CEO and Chief Scientific Officer

Meet The Management Team

Dr. Henry Ji

Chairman, President and CEO

Jerome B. Zeldis

Chief Medical Officer and President of Clinical Research, Medical Affairs and Regulatory

George Ng

Executive Vice President and Chief Administrative and Legal Officer

Dean Ferrigno

Vice President of Finance and Chief Accounting Officer

Alexis Nahama

Vice President of Corporate Development and President Ark Animal Health

Dr. Hui Li

Vice President of Business Development and General Manager of China Operations

Dr. Gunnar F. Kaufmann

Senior Vice President of Immunotherapy & Head of Research and Global Partnerships

Mark R. Brunswick

Vice President of Regulatory Affairs and Quality

Robert Knight

Vice President of Clinical Research

Stephen L. Klincewicz

Vice President of Pharmacovigilance and Clinical Operations

Bill Farley

Vice President of Sales and Business Development

SRNE Research

Sorrento is a revenue generating biopharmaceutical company with a robust development pipeline of clinical trials. The Company is in IND filing for its potential-blockbuster immuno-oncology… Read More

Jan. 12, 2018

For over two decades RedChip Companies has been writing research on small-cap stocks. RedChip was the first to put independent research coverage on Starbucks in 1992. Our research analysts, CFAs, include financial models and target prices based on industry competitors. Our analysts cover dozens of stocks with a focus on healthcare, technology, social media, and consumer goods.

RedChip Companies research reports are distributed to 60,000 opt-in retail, institutional, and accredited investors.

Receive SRNE Email Alerts

*By entering your information you agree to our privacy policy.


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market